Quoin Pharmaceuticals(QNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

QNRX Quoin Pharmaceuticals

Trading 04-24 13:52:01 EDT

5.65

-0.08

-1.40%

High5.74	Low5.32	Vol77.48K
Open5.60	D1 Closing5.73	Amplitude7.33%
Mkt Cap10.19M	Tradable Cap8.14M	Total Shares1.80M
T/O432.82K	T/O Rate5.38%	Tradable Shares1.44M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"QNRX","market":"US","secType":"STK","nameCN":"Quoin Pharmaceuticals","latestPrice":5.65,"timestamp":1777053103723,"preClose":5.73,"halted":0,"volume":77483,"delay":0,"changeRate":-0.013961605584642245,"floatShares":1441399,"shares":1803626,"eps":-14.79626,"marketStatus":"Trading","change":-0.08,"latestTime":"04-24 13:52:01 EDT","open":5.6,"high":5.74,"low":5.32,"amount":432822.98235400004,"amplitude":0.073298,"askPrice":6.3,"askSize":500,"bidPrice":5.55,"bidSize":101,"shortable":3,"etf":0,"ttmEps":-14.79626,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1777060800000},"marketStatusCode":2,"adr":0,"adrRate":35,"exchange":"NASDAQ","adjPreClose":5.73,"preHourTrading":{"tag":"盘前","latestPrice":5.7292,"preClose":5.73,"latestTime":"08:46 EDT","volume":320,"amount":1830.4239039999998,"timestamp":1777034811016,"change":-0.0008,"changeRate":-0.00014,"amplitude":0.005096},"postHourTrading":{"tag":"盘后","latestPrice":5.6,"preClose":5.73,"latestTime":"19:03 EDT","volume":1207,"amount":6806.83,"timestamp":1776985396051,"change":-0.13,"changeRate":-0.022688,"amplitude":0.026178},"volumeRatio":5.283527},"requestUrl":"/m/hq/s/QNRX","defaultTab":"news","newsList":[{"id":"2629005608","title":"Quoin’s QRX003 Trial Moves Forward In Rare Skin Disease, Keeping QNRX On Investor Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2629005608","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629005608?lang=en_us&edition=fundamental","pubTime":"2026-04-22 00:31","pubTimestamp":1776789083,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals Ltd ($QNRX) announced an update on their ongoing clinical study. The multicenter study “A Multicenter, Open-label Study of QR...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/quoins-qrx003-trial-moves-forward-in-rare-skin-disease-keeping-qnrx-on-investor-watch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/quoins-qrx003-trial-moves-forward-in-rare-skin-disease-keeping-qnrx-on-investor-watch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QNRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622961388","title":"Financing Covenants Put Quoin Pharmaceuticals at Heightened Risk of Funding Shortfall and Program Delays","url":"https://stock-news.laohu8.com/highlight/detail?id=2622961388","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622961388?lang=en_us&edition=fundamental","pubTime":"2026-03-28 14:00","pubTimestamp":1774677650,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals Ltd (QNRX) has disclosed a new risk, in the Debt & Financing category. Quoin Pharmaceuticals Ltd. faces heightened financing ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/financing-covenants-put-quoin-pharmaceuticals-at-heightened-risk-of-funding-shortfall-and-program-delays?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/financing-covenants-put-quoin-pharmaceuticals-at-heightened-risk-of-funding-shortfall-and-program-delays?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","QNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622082337","title":"Quoin Pharmaceuticals Ltd : Alliance Global Partners Raises Target Price to $35 From $25","url":"https://stock-news.laohu8.com/highlight/detail?id=2622082337","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622082337?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:03","pubTimestamp":1774609386,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nFWN40F0A0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","QNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622866806","title":"Quoin Pharmaceuticals Ltd reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2622866806","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622866806?lang=en_us&edition=fundamental","pubTime":"2026-03-26 22:09","pubTimestamp":1774534181,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals Ltd reports results for the quarter ended December 31 - Earnings SummaryQuoin Pharmaceuticals Ltd QNRX.OQ reported a quarterly adjusted loss of $14.80 per share for the quarter e","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nL8N40E1FF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622985779","title":"Quoin Pharmaceuticals Q4 EPS $(1.74) Beats $(4.02) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2622985779","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622985779?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:32","pubTimestamp":1774528331,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(1.74) per share which beat the analyst consensus estimate of $(4.02) by 56.72 percent. This is a 85.96 percent increase over losses of $(12.39) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51479392/quoin-pharmaceuticals-q4-eps-1-74-beats-4-02-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622570558","title":"Quoin Pharmaceuticals FY2025 net loss widens 76.34% to $15.8 million; cash climbs 14.85% to $18.7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622570558","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622570558?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:31","pubTimestamp":1774528291,"startTime":"0","endTime":"0","summary":"Quoin published a press release providing a corporate update and reporting fourth-quarter and full-year 2025 financial results.Net loss widened to USD 4.3 million in Q4 2025, and to USD 15.8 million for FY 2025.Research and development expense rose to USD 9.8 million for FY 2025, nearly tripling, while general and administrative expense increased to USD 6.5 million, up 9.5%.Cash, cash equivalents and marketable securities totaled USD 18.7 million at year-end 2025, and Quoin said this is expected to fund operations into 2027.Michael Myers said the company is preparing to initiate a Phase 3 study for QRX003 in Netherton syndrome in 2026 and is targeting an NDA filing in 2027, with topline data from two whole-body Netherton syndrome trials expected in the second half of 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL64PZGH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","QNRX","LU2095319765.USD","IE00BGHQF748.EUR","NDAQ","BK4588","SG9999014021.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","SG9999014013.SGD","BK4585","BK4139","IE00BKPKM429.USD","IE00BN0W2V16.EUR","LU0314104364.USD","LU2210150020.SGD","LU2210149790.SGD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622857777","title":"Press Release: Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2622857777","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622857777?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:30","pubTimestamp":1774528200,"startTime":"0","endTime":"0","summary":"-- Closes Private Placement Financing of Up to $104.5 Million. -- Secures Orphan Drug Designations for QRX003 for Netherton Syndrome  in the U.S. and Europe. -- Advances Proposed Expedited Regulatory Approval Pathways in Japan and Saudi Arabia and Secures Fast Track Designation in the U.S. for QRX003 for NS Subsequent to the End of Q4. -- Reports Continued Clinical Progress for QRX003 in Netherton Syndrome Clinical Studies including Data Supporting Longer Term Durable Treatment Effect and Safety Profile. -- Pediatric NS Study Expanded to 7 Children Now Actively Treated with QRX003, Largest Cohort of This Age Group Ever Studied. -- Ongoing Clinical Data Continues to Support Development of QRX003 as a Treatment for Peeling Skin Syndrome with Study Being Expanded to 6 Subjects. -- Proprietary Rapamycin Topical Platforms Achieve Target Loadings; Clinical Studies Planned in 2H 2026. -- NETHERTON NOW Awareness Campaign Surpasses 2 Million Video Views and 24 Million Global Impressions. ASHBUR","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","QNRX","BK4588","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622851232","title":"Market Sentiment Around Loss-Making Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622851232","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622851232?lang=en_us&edition=fundamental","pubTime":"2026-03-26 18:14","pubTimestamp":1774520089,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals, Ltd. ( NASDAQ:QNRX ) is possibly approaching a major achievement in its business, so we would...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qnrx/quoin-pharmaceuticals/news/market-sentiment-around-loss-making-quoin-pharmaceuticals-lt","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qnrx/quoin-pharmaceuticals/news/market-sentiment-around-loss-making-quoin-pharmaceuticals-lt","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QLD","QQQE","QQQJ","MNQmain","TQQQ","NQmain",".IXIC","QDTE","NVIW.SI","BK4139","SQQQ","QYLG","QNRX","IYW","PSQ","JEPQ","FTEC","GPIQ","QQQY","QID"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2622071996","title":"Quoin Pharmaceuticals Ltd – ADR trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2622071996","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622071996?lang=en_us&edition=fundamental","pubTime":"2026-03-25 21:35","pubTimestamp":1774445756,"startTime":"0","endTime":"0","summary":"09:33 EDT Quoin Pharmaceuticals (QNRX) Ltd – ADR trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-ltd-adr-trading-halted-volatility-trading-pause-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-ltd-adr-trading-halted-volatility-trading-pause-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QNRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622713970","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:33 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2622713970","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622713970?lang=en_us&edition=fundamental","pubTime":"2026-03-25 21:33","pubTimestamp":1774445595,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:33 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nAQN2LRNWA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622907633","title":"Quoin Pharmaceuticals Provides Clinical And Regulatory Update From Constructive Type C Meeting With U.S. FDA For Qrx003 In Netherton Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2622907633","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622907633?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:44","pubTimestamp":1774442692,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals Ltd <2EB0y.F>::*QUOIN PHARMACEUTICALS PROVIDES CLINICAL AND REGULATORY UPDATE FROM CONSTRUCTIVE TYPE C MEETING WITH U.S. FDA FOR QRX003 IN NETHERTON SYNDROME*QUOIN PHARMACEUTICAL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nRSD7GDgvZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622075456","title":"Quoin Pharmaceuticals rises on FDA feedback; single Phase 3 trial may support QRX003 approval in Netherton syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2622075456","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622075456?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:31","pubTimestamp":1774441900,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals said the U.S. FDA indicated that a single Phase 3 study may be sufficient to support marketing approval for QRX003 in Netherton Syndrome.The FDA expressed openness to an alternative Phase 3 design, such as a randomized withdrawal or randomized delayed start study, that would likely not include a traditional upfront vehicle or placebo control.The company plans to submit clinical data from its ongoing Phase 2 and pediatric investigator studies and request a meeting to discuss the data before starting the Phase 3 pivotal program.Quoin Pharmaceuticals said it remains on track to initiate Phase 3 and complete Phase 3 patient recruitment in 2026, and it could file for NDA approval in 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDLb8sLSF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621062180","title":"Quoin Pharmaceuticals Ltd  expected to post a loss of $3.34 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2621062180","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621062180?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:35","pubTimestamp":1774355704,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals Ltd  expected to post a loss of $3.34 a share - Earnings Preview Quoin Pharmaceuticals Ltd QNRX.OQ, QNRX.O is expected to  show no change in quarterly revenue when it reports  re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nL8N40C1DD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620285832","title":"Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620285832","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620285832?lang=en_us&edition=fundamental","pubTime":"2026-03-19 20:30","pubTimestamp":1773923400,"startTime":"0","endTime":"0","summary":"ASHBURN, Va., March  19, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the \"Company\" or \"Quoin\"), a late clinical-stage specialty pharmaceutical company focused on rare and orpha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/19/3258994/0/en/Quoin-Pharmaceuticals-to-Announce-Corporate-Update-and-Fourth-Quarter-and-Full-Year-2025-Financial-Results-on-Thursday-March-26-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618976323","title":"Quoin Pharmaceuticals begins two late-stage whole-body trials of QRX003 4% lotion for Netherton Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2618976323","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618976323?lang=en_us&edition=fundamental","pubTime":"2026-03-12 04:57","pubTimestamp":1773262667,"startTime":"0","endTime":"0","summary":"Quoin said the FDA granted Fast Track designation to QRX003 lotion (4%) for treating Netherton syndrome. QRX003 is being evaluated in two late-stage whole-body clinical trials designed to assess safety and efficacy in patients with Netherton syndrome. The company did not report clinical results in the announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 11, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL9qkBHG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618947659","title":"Quoin Pharmaceuticals receives U.S. Fast Track Designation to QRX003","url":"https://stock-news.laohu8.com/highlight/detail?id=2618947659","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618947659?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:38","pubTimestamp":1773232725,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals (QNRX) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to QRX003 lotion for the treat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-receives-u-s-fast-track-designation-to-qrx003-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-receives-u-s-fast-track-designation-to-qrx003-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QNRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618748942","title":"FDA grants Fast Track designation to Quoin's QRX003 for Netherton syndrome treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2618748942","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618748942?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:30","pubTimestamp":1773232223,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals said the U.S. FDA granted Fast Track designation to its QRX003 lotion (4%) for Netherton Syndrome, a regulatory status intended to speed development and potentially accelerate review. The company noted QRX003 previously received FDA Pediatric Rare Disease and Orphan Drug designations, and EMA Orphan Drug designation, which can provide incentives such as market exclusivity upon approval, tax credits and fee reductions.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL2NZgz0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU0314104364.USD","BK4139","SG9999014005.SGD","BK4588","NDAQ","SG9999014013.SGD","BK4585","IE00BKPKM429.USD","LU2210150020.SGD","QNRX","IE00B64PRP62.GBP","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014021.USD","LU2210149790.SGD","SG9999014039.USD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618626560","title":"Quoin Pharmaceuticals Ltd  expected to post a loss of $3.34 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2618626560","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618626560?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:34","pubTimestamp":1773059650,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals Ltd  expected to post a loss of $3.34 a share - Earnings Preview Quoin Pharmaceuticals Ltd QNRX.OQ, QNRX.O is expected to  show no change in quarterly revenue when it reports  re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL8N3ZX13Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614403490","title":"Quoin Pharmaceuticals highlights continued growth of NETHERTON NOW program","url":"https://stock-news.laohu8.com/highlight/detail?id=2614403490","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614403490?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:53","pubTimestamp":1772114033,"startTime":"0","endTime":"0","summary":"In recognition of Rare Disease Day 2026, Quoin Pharmaceuticals (QNRX) highlighted the continued growth of its NETHERTON NOW awareness campaign, whi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-highlights-continued-growth-of-netherton-now-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-highlights-continued-growth-of-netherton-now-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0158827948.USD","BK4503","LU1988902786.USD","LU2458330169.SGD","IE00B19Z9P08.USD","BK4588","BK4608","LU2433249047.HKD","LU0265550946.USD","BK4097","IE00B894F039.SGD","QNRX","LU0082616367.USD","BK4139","LU2111349929.HKD","LU1989764748.USD","LU2286300806.USD","LU2125909916.SGD","BK4601","LU1323610961.USD","LU1267930730.SGD","LU0823434740.USD","NOWL","LU0823434583.USD","LU1923622614.USD","LU0820561818.USD","LU1923623000.USD","LU2087625088.SGD","BK4613","BK4543","LU0708995401.HKD","LU0081259029.USD","BK4528","LU1551013425.SGD","LU1551013342.USD","LU0316494557.USD","LU2023250843.SGD","IE00B19Z9Z06.USD","BK4581","BK4585","LU1153585028.USD","LU1923622291.USD","LU2089283258.USD","LU0109391861.USD","LU2106854487.HKD","LU1803068979.SGD","LU1917777945.USD","LU2125909247.SGD","LU2381873111.SGD","LU2023251221.USD","LU0689472784.USD","BK4550","LU0353189680.USD","LU0011850046.USD","LU1951200564.SGD","BK4534","LU1989772923.USD","LU0265550359.USD","LU2089284900.SGD","LU0719512351.SGD","LU0353189763.USD","LU1064131342.USD","LU0354030438.USD","IE00BMPRXN33.USD","LU0889565833.HKD","LU2543165471.USD","IE00BMPRXR70.SGD","LU0354030511.USD","LU2125909593.SGD","LU2458330243.SGD","BK4566","LU2063271972.USD","LU1989764664.SGD","LU0158827781.USD","LU1116320901.HKD","LU0820561909.HKD","BK4607","LU1116320737.USD","LU2125909759.SGD","LU0672654240.SGD","LU0943347566.SGD","LU2028103732.USD","LU1974910355.USD","LU0109392836.USD","LU0348723411.USD","LU0320765059.SGD","LU2264538146.SGD","LU2023250504.SGD","LU2271345857.HKD","LU1989772840.SGD","IE00BZ9MQY76.HKD","LU1951198990.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614422210","title":"NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2614422210","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614422210?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:30","pubTimestamp":1772112600,"startTime":"0","endTime":"0","summary":"Videos on the NETHERTON NOW website have been viewed 2 million times with 24 million impressions. Patients, families, and clinicians share the reality of living with Netherton Syndrome, a rare genetic skin disease with no approved treatment, and the enduring hope for a cure","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/26/3245592/0/en/NETHERTON-NOW-Recognizes-Rare-Disease-Day-and-Highlights-Growing-Global-Awareness-of-Netherton-Syndrome.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2543165471.USD","LU0320765059.SGD","LU1974910355.USD","LU0354030438.USD","QNRX","BK4097","LU2271345857.HKD","LU2125909247.SGD","BK4503","LU1116320737.USD","LU2023251221.USD","LU2458330243.SGD","LU0348723411.USD","BK4550","BK4608","LU0719512351.SGD","LU1116320901.HKD","LU0081259029.USD","LU1064131342.USD","LU2028103732.USD","LU1153585028.USD","LU0353189763.USD","LU0082616367.USD","LU0943347566.SGD","LU0265550946.USD","IE00BMPRXR70.SGD","LU1988902786.USD","BK4543","LU0353189680.USD","LU0158827948.USD","LU0820561818.USD","LU0823434583.USD","LU0889565833.HKD","LU1923622291.USD","LU0820561909.HKD","LU1923623000.USD","IE00BMPRXN33.USD","LU2023250504.SGD","IE00BZ9MQY76.HKD","LU1323610961.USD","BK4607","LU2089283258.USD","LU2381873111.SGD","LU2089284900.SGD","IE00B894F039.SGD","LU2106854487.HKD","NOWL","LU1989764664.SGD","BK4581","LU0689472784.USD","LU0158827781.USD","LU1551013425.SGD","LU0011850046.USD","LU2087625088.SGD","IE00B19Z9P08.USD","LU2125909593.SGD","LU2264538146.SGD","LU1951198990.SGD","BK4613","LU0354030511.USD","LU1989772923.USD","LU2286300806.USD","LU2023250843.SGD","LU2111349929.HKD","BK4566","LU1989772840.SGD","LU0109392836.USD","LU1989764748.USD","LU1803068979.SGD","LU0672654240.SGD","BK4588","LU2125909759.SGD","LU2063271972.USD","LU1951200564.SGD","BK4528","BK4585","BK4139","LU2458330169.SGD","LU0316494557.USD","LU2125909916.SGD","IE00B19Z9Z06.USD","LU0265550359.USD","ETH","LU1267930730.SGD","BK4534","LU0823434740.USD","BK4601","LU1551013342.USD","LU0708995401.HKD","LU1917777945.USD","LU1923622614.USD","LU0109391861.USD","LU2433249047.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.quoinpharma.com","stockEarnings":[{"period":"1week","weight":-0.1292},{"period":"1month","weight":-0.2837},{"period":"3month","weight":-0.4031},{"period":"6month","weight":-0.5575},{"period":"1year","weight":-0.1265},{"period":"ytd","weight":-0.6029}],"compareEarnings":[{"period":"1week","weight":0.0097},{"period":"1month","weight":0.0846},{"period":"3month","weight":0.0279},{"period":"6month","weight":0.0461},{"period":"1year","weight":0.3232},{"period":"ytd","weight":0.0389}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. operates as a subsidiary of Skinvisible, Inc.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.264124},{"month":2,"riseRate":0.2,"avgChangeRate":-0.199382},{"month":3,"riseRate":0.2,"avgChangeRate":-0.222445},{"month":4,"riseRate":0.2,"avgChangeRate":-0.173847},{"month":5,"riseRate":0.5,"avgChangeRate":0.000391},{"month":6,"riseRate":0.5,"avgChangeRate":-0.071654},{"month":7,"riseRate":0.5,"avgChangeRate":-0.033987},{"month":8,"riseRate":0.5,"avgChangeRate":-0.098098},{"month":9,"riseRate":0,"avgChangeRate":-0.208503},{"month":10,"riseRate":0.5,"avgChangeRate":0.22434},{"month":11,"riseRate":0.4,"avgChangeRate":0.035616},{"month":12,"riseRate":0.2,"avgChangeRate":-0.187047}],"exchange":"NASDAQ","name":"Quoin Pharmaceuticals","nameEN":"Quoin Pharmaceuticals","securityTypeName":"DR","adrRate":"1:35"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Quoin Pharmaceuticals(QNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Quoin Pharmaceuticals(QNRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Quoin Pharmaceuticals,QNRX,Quoin Pharmaceuticals股票,Quoin Pharmaceuticals股票老虎,Quoin Pharmaceuticals股票老虎国际,Quoin Pharmaceuticals行情,Quoin Pharmaceuticals股票行情,Quoin Pharmaceuticals股价,Quoin Pharmaceuticals股市,Quoin Pharmaceuticals股票价格,Quoin Pharmaceuticals股票交易,Quoin Pharmaceuticals股票购买,Quoin Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Quoin Pharmaceuticals(QNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Quoin Pharmaceuticals(QNRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}